With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Five months after Amgen and Novartis outlined their second batch of positive Phase III data for their CGRP migraine drug erenumab, the two giants have reworked their commercial partnership to give Novartis a piece of the US market — for a price.
Under their original deal Amgen was left in charge of the US, but now Novartis has agreed to cover part of the commercialization costs in exchange for a slice of the revenue in the all-important market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.